A federal judge has declined to dismiss claims that Johnson & Johnson is unfairly suppressing competition of its anti-inflammatory drug Remicade.

U.S. District Judge J. Curtis Joyner of the Eastern District of Pennsylvania on Aug. 10 declined to grant J&J’s motion to dismiss the lawsuit Pfizer v. Johnson & Johnson. The ruling allows Pfizer to proceed with the antitrust lawsuit it brought against J&J on allegations that rebate programs J&J entered into with insurers and hospitals were designed to curb competition with Pfizer’s biosimilar anti-inflammatory medication called Inflectra.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]